CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

The trial targets individuals with relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes.

Nucala gains new indication; FDA implements stricter guidance for COVID-19 vaccine approval; pruritus reported following discontinuation of long-term antihistamines; antibiotic looks promising for ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

Quality of Life Matters: It Is Time to Integrate Scalp Cooling in Routine Clinical Practice There is a clear economic incentive for dose rounding down to a vial size to reduce product wastage.